Chronic Pain
Methodology & AI Transparency ⓘ
Chronic Pain Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is chronic pain? Pain is a signal from your nervous system that something may be wrong.
- 2 Real-world patient consensus: Mapped to Neuropathy, Fibromyalgia & Chronic Pain under ICD-10-CM G58.7 for Chronic Pain clinical workups.
- 3 Typical cash cost range: Clinicians assessing Chronic Pain focus on ectopic dorsal root in Chronic Pain (G58.7: ganglion sodium-channel firing) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Chronic Pain monitoring tracks hs-CRP & ESR in Chronic Pain (G58.7: Inflammatory Check) toward hs-CRP < 1.0 mg/L (G58.7).
Ask our AI Specialists anything about Chronic Pain
What Is Chronic Pain?
What is chronic pain? Pain is a signal from your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. You may feel pain in one area of your body or all over. Each person feels pain differently, even if the reason for the pain is the same. Pain might be acute or chronic. The type of pain is based on how long and how often you have pain. Acute pain starts suddenly and goes away when the cause is treated or healed. This pain lets you know that you may be injured or have a problem you need to take care of.
Pathophysiology, Underlying Causes & Clinical Presentation
In Chronic Pain (G58.7), physiological disruption stems from ectopic dorsal root in Chronic Pain (G58.7: ganglion sodium-channel firing), Cross-referenced with NIH MeSH (Chronic Pain), informing Neuropathy, Fibromyalgia & Chronic Pain protocols that track HbA1c & 2-Hour in Chronic Pain (G58.7: Glucose Tolerance) (HbA1c < 5.6% (G58.7)).
Common Symptoms & Clinical Signs
- • Headaches or migraines
- • Ask you about your medical history
- • Presentation of Chronic Pain (G58.7): widespread musculoskeletal tender in Chronic Pain (G58.7: points accompanied by)
- • Secondary Chronic Pain clinical sign: localized nerve entrapment in Chronic Pain (G58.7: numbness or radiating)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Chronic Pain Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G58.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neuropathy, Fibromyalgia & Chronic Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & ESR in Chronic Pain (G58.7: Inflammatory Check) | hs-CRP < 1.0 mg/L (G58.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & 2-Hour in Chronic Pain (G58.7: Glucose Tolerance) | HbA1c < 5.6% (G58.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12 & in Chronic Pain (G58.7: Methylmalonic Acid) | B12 > 500 pg/mL (G58.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Chronic Pain
Treatment selection for Chronic Pain depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Chronic Pain)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and real-world benefits of Semaglutide in Patients With Chronic Kidney: What a 12,785-Participant Study Found Semaglutide demonstrates a favourable safety profile and significant cardiorenal benefits in CKD patients, with or without T2DM. Endocrinology, diabetes & metabolism • 2025-11-15 • Meta-Analysis | N = 12,785 | 99/100 | PMID 41276951 ↗ |
| New Insights on Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart: What a 3,668-Participant Study Found Compared with placebo, a mean atrasentan exposure translated in a hazard ratio of 0.76 (95% confidence interval (CI): 0.28-0.85) for kidney events and 1.13 (95% CI: 1.03-2.20) for heart failure events. Clinical pharmacology and therapeutics • 2021-06-15 • Phase III Randomized Trial | N = 3,668 | 96/100 | PMID 33338269 ↗ |
| New Insights on Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney: What a 6,609-Participant Study Found 1995 participants (1035 placebo, 960 empagliflozin) had ≥1 ACH (1895 ACH in placebo and 1611 in the empagliflozin 10-mg groups). Clinical therapeutics • 2025-12-15 • Phase III Randomized Trial | N = 6,609 | 96/100 | PMID 41047325 ↗ |
| New Insights on Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development,: What a 5,000-Participant Study Found Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Medicine • 2023-07-01 • Phase III Randomized Trial | N = 5,000 | 96/100 | PMID 37499085 ↗ |
| New Insights on Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic: What a 2,639-Participant Study Found Overall (N = 2,639; 3 mg of plecanatide [n = 877]; 6 mg of plecanatide [n = 877]; and placebo [n = 885]), CSBM responder rates were significantly greater with 3 mg of plecanatide and 6 mg of plecanatide vs placebo in subgroups... Clinical and translational gastroenterology • 2023-07-01 • Phase III Randomized Trial | N = 2,639 | 96/100 | PMID 37162147 ↗ |
Chronic Pain Patient Community & “People Like Me” Threads
Filter Chronic Pain community threads and patient logs by age, biological sex, dosage, and treatment duration.